SARS-CoV-2 Genotyping Highlights the Challenges in Spike Protein Drift Independent of Other Essential Proteins.

SARS-CoV-2 Genotyping Highlights the Challenges in Spike Protein Drift Independent of Other Essential Proteins.

Publication date: Sep 09, 2024

As of 2024, SARS-CoV-2 continues to propagate and drift as an endemic virus, impacting healthcare for years. The largest sequencing initiative for any species was initiated to combat the virus, tracking changes over time at a full virus base-pair resolution. The SARS-CoV-2 sequencing represents a unique opportunity to understand selective pressures and viral evolution but requires cross-disciplinary approaches from epidemiology to functional protein biology. Within this work, we integrate a two-year genotyping window with structural biology to explore the selective pressures of SARS-CoV-2 on protein insights. Although genotype and the Spike (Surface Glycoprotein) protein continue to drift, most SARS-CoV-2 proteins have had few amino acid alterations. Within Spike, the high drift rate of amino acids involved in antibody evasion also corresponds to changes within the ACE2 binding pocket that have undergone multiple changes that maintain functional binding. The genotyping suggests selective pressure for receptor specificity that could also confer changes in viral risk. Mapping of amino acid changes to the structures of the SARS-CoV-2 co-transcriptional complex (nsp7-nsp14), nsp3 (papain-like protease), and nsp5 (cysteine protease) proteins suggest they remain critical factors for drug development that will be sustainable, unlike those strategies targeting Spike.

Open Access PDF

Concepts Keywords
Base COVID-19
Genotyping cysteine protease
Healthcare drift
Viral nonstructural protein
papain-like protease
SARS-CoV-2
Spike
viral genome

Semantics

Type Source Name
disease IDO protein
drug DRUGBANK Amino acids
drug DRUGBANK Papain
drug DRUGBANK Coenzyme M
disease MESH Infectious Diseases
pathway REACTOME Infectious disease
disease IDO infectious disease
disease MESH COVID 19
disease IDO history
disease IDO blood
disease IDO country
disease IDO geographical region
disease IDO virulence
disease IDO algorithm
disease IDO process
pathway KEGG Ribosome
drug DRUGBANK L-Arginine
drug DRUGBANK L-Glutamine
drug DRUGBANK L-Tyrosine
drug DRUGBANK L-Asparagine
drug DRUGBANK Histidine
drug DRUGBANK L-Phenylalanine
drug DRUGBANK L-Valine
drug DRUGBANK Proline
drug DRUGBANK Glycine
drug DRUGBANK Serine
drug DRUGBANK L-Cysteine
disease IDO site
disease MESH confusion
disease IDO replication
drug DRUGBANK Guanine
disease IDO cell
pathway KEGG Viral replication
disease IDO host
disease MESH dengue
disease MESH Hepatitis
disease MESH influenzas
drug DRUGBANK Spinosad
drug DRUGBANK Ritonavir
drug DRUGBANK Troleandomycin
disease MESH Clinical Significance
drug DRUGBANK Isosorbide Mononitrate
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO infectivity
disease MESH HIV Infection
pathway REACTOME HIV Infection
disease IDO intervention
disease MESH Cancer

Original Article

(Visited 1 times, 1 visits today)